EGON-ZEHNDER
17.4.2018 13:02:06 CEST | Business Wire | Press release
The Chief Executive Officers of some of the world’s largest companies reveal they struggle most with the human demands of the role. While CEOs feel confident in their experience and operational know-how when they reach the position, they recognize the need to transform themselves in order to keep up with the pace of disruption to business.
402 CEOs from companies headquartered in 11 countries – who lead organizations with estimated combined revenues of USD $2.6 trillion– shared their leadership experiences in Egon Zehnder’s global study The CEO: A Personal Reflection.
“The pressures on CEOs today have never been greater. While CEOs have the capabilities and experience to assume the role, the complexities of leading – influencing, advocating, collaborating and innovating – pose challenges even to the best leaders,” said Kati Najipoor-Schuette, Global CEO Practice Group Leader at Egon Zehnder.
“In today’s complex and volatile world, CEOs must have both the hard and soft skills. The very best leaders are on a continuous journey of learning and transforming themselves while also transforming their businesses,” noted Dick Patton, Global CEO Practice Group Leader, Egon Zehnder.
Rajeev Vasudeva, Chief Executive Officer of Egon Zehnder, added “An organization is only as successful as its leader’s ability to manage a multitude of short- and long-term priorities. What’s required is their human side of leadership: a CEO who embraces humility and vulnerability and who remains open to feedback, self-discovery and continuous learning. This ability to self-transform is the key to transforming their organizations as well.”
Key findings:
Data from The CEO: A Personal Reflection explore the human side of the CEO role. Key findings from the report include:
A majority of CEOs feel they have the hard skills and professional experience to step up to the role, but found certain personal aspects of the role more challenging than expected:
- 74% of CEOs said their prior achievements and experience prepared them to be CEOs, however:
- 47% of respondents said that developing their senior leadership team was more difficult than anticipated.
- 50% of respondents said driving culture change was more difficult than they’d thought.
- 48% of respondents said that finding time for themselves and for self-reflection was more difficult than expected.
- With hindsight, only 32% felt fully prepared.
Recognizing the importance of these soft skills and their need to adapt and change, today’s CEO is moving toward a more reflective and collaborative approach to leadership.
- 54% of CEOs agreed that transitioning into the role required an intense period of personal reflection.
- 79% of CEOs recognized they needed the capacity to transform themselves as well as their business.
- Only 57% of CEOs said they were comfortable showing emotions.
- 78% of CEOs said they were comfortable admitting mistakes.
Many CEOs felt they lacked some necessary supports before making the step up. Some believe that the succession process needs work. In particular, CEOs appointed from within a company tend to feel less prepared compared with those hired from outside.
-
44% of the CEOs surveyed said that their appointment was not part of a
planned and formal succession process.
- For externally promoted CEOs that was 54%
- For internally promoted CEOs that was 36%
- Only 28% of internally-selected CEOs said they felt fully prepared vs 38% of external hires.
- 65% of respondents said there was some succession planning underway for their own successors, but only 32% of them said that there was currently a clear process in place.
- Only 38% of respondents said they turned to their Chairman for honest feedback, and only 28% turn to their Board.
To read the full report and explore the survey data, visit: https://www.egonzehnder.com/ceo-study-2018/
About Egon Zehnder
Egon Zehnder is the world’s leadership advisory firm, sharing one goal: to transform people, organizations, and the world through great leadership. We know what great leaders can do and are passionate about delivering the best leadership solutions for our clients. As One Firm, our more than 450 Consultants in 68 offices and 40 countries bring our individual strengths to form one powerful collaborative team. We partner closely with public and private corporations, family-owned enterprises, and non-profit and government agencies to provide Board advisory services, CEO search and succession, executive search, executive assessment, leadership development, and organizational transformation. We share a commitment to and pride in doing work that contributes to successful careers, stronger companies, and a better world. For more information, visit www.egonzehnder.com and follow us on LinkedIn and Twitter .
About Egon Zehnder’s CEO Practice
Over the past five years, we have applied our own future-oriented, proprietary approach to more than 1,800 CEO mandates. We understand that the Chief Executive role is unique, particularly in the current atmosphere of complexity and volatility. These uncertainties require a pragmatic and aligned view on the business and leadership requirements of the CEO, one that must be reviewed regularly over the course of a transition.
We aim to partner with our clients in all aspects of the CEO leadership journey. That journey begins by aligning with your Board regarding the company’s future transformational needs and CEO requirements. We then help you build a compelling internal pipeline of senior leaders with CEO potential by identifying, assessing, and advising them on their development journey.
The CEO transition process also means working hand-in-hand with your Board of Directors to develop a clear, workable succession plan—one that helps internal executives accelerate their personal development through our heralded Executive Breakthrough Program, designed and facilitated in partnership with Mobius Executive Leadership. Once you’ve selected your CEO, we can apply our “Accelerated CEO Impact” program to assist in onboarding. This bespoke option begins before the CEO’s first day and helps make their first 100 days and beyond a success.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180417005636/en/
Contact:
Media inquiries:
Egon Zehnder
Hilary
Crnkovich,
+1 312 260 8978
Global Head of Marketing and
Communications
hilary.crnkovich@egonzehnder.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
